Last reviewed · How we verify

Norvir — Competitive Intelligence Brief

Norvir (ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cytochrome P450 3A Inhibitor [EPC]. Area: Oncology.

marketed Cytochrome P450 3A Inhibitor [EPC] Cytochrome P450 2C9 Oncology Live · refreshed every 30 min

Target snapshot

Norvir (ritonavir) — AbbVie. Norvir works by blocking the cytochrome P450 3A enzyme, which helps increase the levels of other medications in the body.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Norvir TARGET ritonavir AbbVie marketed Cytochrome P450 3A Inhibitor [EPC] Cytochrome P450 2C9 1996-01-01
Propecia finasteride Merck & Co. marketed 5-alpha-reductase inhibitor 3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9 1992-06-19
Diflucan fluconazole Pfizer Inc. marketed Azole Antifungal [EPC] Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase 1990-01-29
Profenol SUPROFEN Novartis marketed suprofen Cytochrome P450 2C9, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2 1988-01-01
Phenylbutazon PHENYLBUTAZONE Novartis marketed phenylbutazone Nicotinate phosphoribosyltransferase, Prostacyclin synthase, Cytochrome P450 2C9 1980-01-01
Sulfabid SULFAPHENAZOLE Purdue Frederick marketed sulfaphenazole Cytochrome P450 2C9, Dihydropteroate synthase 1974-01-01
Coumadin warfarin Generic (originally Wisconsin Alumni Research Foundation) marketed Vitamin K antagonist (anticoagulant) Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 1954-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cytochrome P450 3A Inhibitor [EPC] class)

  1. · 2 drugs in this class
  2. Gilead Sciences · 2 drugs in this class
  3. AbbVie · 1 drug in this class
  4. Abbvie Deutschland Gmbh Co. Kg · 1 drug in this class
  5. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norvir — Competitive Intelligence Brief. https://druglandscape.com/ci/ritonavir. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: